11/09/17 -9:45 AM to 11:00 AM
Department Seminar: Louis-Charles Campeau, Ph.D.
"Total Synthesis in the Real World: Tales from the Process Chemistry Hood"
Phosphoramidate prodrugs are a critical component of life-saving pro-nucleotide (ProTide) therapies used in the treatment of viral disease and cancer. Despite their widespread use and commercial value, the catalytic stereoselective synthesis of P-stereogenic ProTide therapeutics remains an unsolved problem in organic synthesis. In addition, nucleoside chemistry has been a neglected field in recent history with many academic laboratories moving away from carbohydrate chemistry. Charged with developing processes for the large-scale production, process chemists are faced with the challenge of balancing yield and robustness of a chemical process with its cost and sustainability. This presentation will discuss the development of a novel total synthesis of MK-3682, a ProTide therapeutic under investigation for the treatment of Hepatitis C. New reactivity and insights into novel reactions, catalytic and otherwise, reaction mechanism and process development for implementation on large scale will be discussed.
“A Perspective on a Career in the Pharmaceutical Industry”
4 p.m. Thursday, Nov. 9
Kate and Michael Bárány Conference Room (117/119 Smith Hall)
About Louis-Charles Campeau, Ph.D.
Louis-Charles (LC) Campeau obtained his doctorate degree with the late Professor Keith Fagnou at the University of Ottawa in Canada as a Natural Sciences and Engineering Research Council of Canada post-graduate scholar, after completing his Bachelor of Science in biopharmaceutical sciences. He first joined Merck Research Laboratories at Merck-Frosst in Montreal in 2007. During his tenure at Merck-Frosst, Campeau accrued several scientific accomplishments and pipeline impacts, including key contributions to the discovery of Doravirine (MK-1439). In 2010, he moved from Montreal to New Jersey, where he has served in roles of increasing responsibility ever since. After his roles as director and head of the Catalysis and Automation Laboratory and then director in Process Chemistry, where he led teams through very challenging assignments on manufacturing route development to new products, Campeau was appointed executive director in Process Research. He is currently the head of the Discovery Process Chemistry organization, leading a team of smart creative scientists at all Merck Discovery sites, responsible for eliminating synthetic bottlenecks to accelerate the discovery of novel therapeutics. His passion for scientific excellence is exemplified by 55 publications and patents, several successful collaborations with key academics, and an extensive list of invited lectures worldwide. He was awarded the Pierre Labèrge Prize for the best doctorate thesis in the Sciences (2008), Merck Special Achievement Award for his significant contributions to the discovery of Doravirine (MK-1439) in 2010, and recently received the Young Alumni Award of Excellence, University of Ottawa, Faculty of Science (2016).ni Award of Excellence, University of Ottawa, Faculty of Science (2016).
Event DetailsLocation: 331 Smith HallHost: Professor Joseph TopczewskiSpeakers:
- Louis-Charles Campeau, Ph.D.
- Department of Process and Analytical Chemistry
- Merck Research Laboratories